Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm*, Debra Fayter, Bram L. T. Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen, Manuela A. Joore

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)1195-1207
Number of pages13
JournalPharmacoeconomics
Volume37
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • BRENTUXIMAB VEDOTIN
  • HEALTH
  • DESIGN

Cite this